ASLN
Income statement / Annual
Last year (2023), ASLAN Pharmaceuticals Limited's total revenue was $12.00 M,
and the percentage change from the previous year is not available.
In 2023, ASLAN Pharmaceuticals Limited's net income was -$44.22 M.
See ASLAN Pharmaceuticals Limited’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$12.00 M
|
$0.00
|
$0.00
|
$0.00
|
$3.00 M
|
$0.00
|
$0.00
|
$11.49 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$348,498.00 |
$331,752.00 |
$282,224.00 |
$297,758.00 |
$407,259.00 |
$241,556.00 |
$209,087.00 |
$124,370.00 |
$52,087.00 |
$0.00 |
| Gross Profit |
$11.65 M |
-$331,752.00 |
-$282,224.00 |
-$297,758.00 |
$2.59 M |
-$241,556.00 |
-$209,087.00 |
$11.36 M |
-$52,087.00 |
$0.00 |
| Gross Profit Ratio |
0.97 |
0 |
0 |
0 |
0.86 |
0 |
0 |
0.99 |
0 |
0 |
| Research and Development
Expenses |
$42.50 M
|
$38.00 M
|
$22.02 M
|
$9.31 M
|
$16.59 M
|
$31.83 M
|
$30.62 M
|
$13.10 M
|
$6.22 M
|
$4.50 M
|
| General & Administrative
Expenses |
$13.24 M
|
$9.88 M
|
$11.83 M
|
$7.17 M
|
$8.51 M
|
$10.51 M
|
$9.33 M
|
$6.92 M
|
$6.61 M
|
$2.82 M
|
| Selling & Marketing
Expenses |
-$348,498.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$12.89 M
|
$9.88 M
|
$11.83 M
|
$7.17 M
|
$8.51 M
|
$10.51 M
|
$9.33 M
|
$6.92 M
|
$6.61 M
|
$2.82 M
|
| Other Expenses |
-$11,127.00 |
$356,555.00 |
$2.21 M |
$758,747.00 |
$23.07 M |
$244,589.00 |
-$235.83 |
-$0.00 |
-$40,333.48 |
$5,456.42 |
| Operating Expenses |
$55.39 M |
$47.88 M |
$33.85 M |
$16.48 M |
$48.17 M |
$42.35 M |
$39.94 M |
$20.02 M |
$12.84 M |
$7.31 M |
| Cost And Expenses |
$55.74 M |
$47.88 M |
$33.85 M |
$16.48 M |
$48.58 M |
$42.35 M |
$39.94 M |
$20.14 M |
$12.84 M |
$7.31 M |
| Interest Income |
$404,981.00 |
$354,457.00 |
$219.00 |
$592.00 |
$150,610.00 |
$268,330.00 |
$370,589.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$4.33 M |
$3.68 M |
$1.86 M |
$1.25 M |
$901,612.00 |
$491,904.00 |
$425,268.00 |
$521,505.00 |
$986,928.00 |
$295,403.00 |
| Depreciation &
Amortization |
$348,498.00
|
$331,752.00
|
$282,224.00
|
$297,758.00
|
$444,412.00
|
$241,556.00
|
$209,087.00
|
$75,998.00
|
$48,908.00
|
$24,853.00
|
| EBITDA |
-$43.39 M
|
-$47.61 M
|
-$32.04 M
|
-$15.72 M
|
-$45.76 M
|
-$41.44 M
|
-$40.07 M
|
-$8.41 M
|
-$12.29 M
|
-$7.04 M
|
| EBITDA Ratio |
-3.62 |
0 |
0 |
0 |
-15.25 |
0 |
0 |
-0.73 |
0 |
0 |
| Operating Income Ratio
|
-3.64
|
0
|
0
|
0
|
-15.19
|
0
|
0
|
-0.75
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$342,753.00
|
-$2.97 M
|
$2.26 M
|
-$487,992.00
|
-$986,276.00
|
$176,913.00
|
-$767,727.68
|
-$289,500.68
|
-$1.14 M
|
-$49,517.80
|
| Income Before Tax |
-$44.08 M |
-$51.28 M |
-$31.59 M |
-$16.97 M |
-$46.66 M |
-$42.17 M |
-$40.71 M |
-$9.00 M |
-$13.33 M |
-$7.36 M |
| Income Before Tax Ratio
|
-3.67
|
0
|
0
|
0
|
-15.55
|
0
|
0
|
-0.78
|
0
|
0
|
| Income Tax Expense |
$132,667.00 |
$99,221.00 |
$3.12 M |
$934,921.00 |
$408,002.00 |
$14,439.00 |
-$342,458.83 |
$173,835.00 |
$500,028.00 |
$245,885.00 |
| Net Income |
-$44.22 M |
-$51.38 M |
-$34.71 M |
-$17.91 M |
-$47.07 M |
-$42.19 M |
-$40.71 M |
-$9.00 M |
-$13.33 M |
-$7.36 M |
| Net Income Ratio |
-3.68 |
0 |
0 |
0 |
-15.69 |
0 |
0 |
-0.78 |
0 |
0 |
| EPS |
-2.69 |
-3.68 |
-2.66 |
-2.33 |
-7.25 |
-7.04 |
-8.18 |
-1.73 |
-6.05 |
-28.81 |
| EPS Diluted |
-2.69 |
-3.68 |
-2.66 |
-2.33 |
-7.25 |
-7.04 |
-7.82 |
-1.73 |
-6.05 |
-28.81 |
| Weighted Average Shares
Out |
$16.45 M
|
$13.95 M
|
$13.03 M
|
$7.69 M
|
$6.50 M
|
$5.99 M
|
$4.98 M
|
$5.20 M
|
$2.20 M
|
$255,588.00
|
| Weighted Average Shares
Out Diluted |
$16.45 M
|
$13.95 M
|
$13.03 M
|
$7.69 M
|
$6.50 M
|
$5.99 M
|
$5.20 M
|
$5.20 M
|
$2.20 M
|
$255,588.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
